Immune-inflammatory (autoimmune and autoinflammatory) rheumatic diseases are
widespread severe chronic inflammatory diseases and also “models” for studying the …

Systemic lupus erythematosus was diagnosed in a patient at 43 years old. When proteinuria
recurred at 57 years old, the first kidney biopsy was performed, and class IV-G (A)+ V lupus …

Glucocorticoids (GCs) have long been one of the cornerstones of the treatment of systemic
lupus erythematosus (SLE). However, for many years, recommendations for GC therapy …

Introdução: O acometimento renal se manifesta geralmente no início do lúpus eritematoso
sistêmico (LES) e sua incidência diminui significativamente após os primeiros 5 anos do …

Introducción y objetivo Belimumab es un anticuerpo monoclonal aprobado para pacientes
con lupus eritematoso sistémico (LES), con indicación reciente para nefritis lúpica (NL). El …

Autoimmune diseases are chronic, uncured, life-altering illnesses caused by immune cells
mistakenly attacking and damaging host tissues. While genetic predispositions play a vital …

Systemic lupus erythematosus (SLE) is a long-term multisystem autoimmune rheumatic
disease that can affect the skin, joints, kidneys, lungs, heart, and central nervous system …

Background The goal of targeted treatment in patients with Systemic Lupus Erythematosus
(SLE) is to achieve clinical remission or low disease activity, with the best quality of life, low …

Background Hydroxychloroquine (HCQ), a cornerstone drug, is recommended for long-term
use in treating systemic lupus erythematosus (SLE). However, in cases where HCQ is …

Background: Pediatric lupus nephritis (LN) is one of the most serious manifestations of
systemic lupus erythematosus (SLE) in children, determining the outcomes of the disease …